MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer

Carlos Ferrer Albiach; Enrique Ochoa Aranda; Alfonso Gomez Iturriaga-Piña; Amalia Sotoca Ruiz; Fernando López Campos; Mariano Porras Martinez; Raquel García Gómez; Manel Algara Lopez; Virginia Ramos Fernandez; Antonio Conde Moreno; Susana Ors; Esther Flores; Francisco Garcia Piñón

doi:doi:10.11648/j.jctr.20190702.12

MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer

Carlos Ferrer Albiach, Enrique Ochoa Aranda, Alfonso Gomez Iturriaga-Piña, Amalia Sotoca Ruiz, Fernando López Campos, Mariano Porras Martinez, Raquel García Gómez, Manel Algara Lopez, Virginia Ramos Fernandez, Antonio Conde Moreno, Susana Ors, Esther Flores, Francisco Garcia Piñón

Published in Journal of Cancer Treatment and Research (Volume 7, Issue 2)

Received: 17 June 2019 Accepted: 19 July 2019 Published: 6 August 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.

Published in	Journal of Cancer Treatment and Research (Volume 7, Issue 2)
DOI	10.11648/j.jctr.20190702.12
Page(s)	33-40
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Microrna, Paraffin Blocks, Prostate Cancer, MetÁstasis Biology, Oligometastasis

References

[1]	https://www.cancer.net/es/tipos‑de‑cáncer/cáncer‑de‑próstata/estadísticas
[2]	Ost P, Reynders D, Decaestecker K, Fonteyne V, Nicolaas Lumen N, et al (2018). Surveillance or metastasis‑directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. J Clin Oncol. Feb 10; 36(5): 446-453.
[3]	Kim J, Soo Park J, Sik Ham W (2017): The role of metastasis‑directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer. Investig Clin Urol; 58: 307‑316.
[4]	Phillips R, Ost P. T Tran P (2017): What role does stereotactic ablative radiotherapy have in advanced castrate‑resistant prostate cancer Future Oncology. 11 October 10.2217/fon‑2017‑ 0337
[5]	Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR‑COMET) NCT01446744.
[6]	Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image‑Guided Radiation Therapy. Verified March 2012 by Memorial Sloan‑Kettering Cancer Center Sponsor: Memorial Sloan‑Kettering Cancer Center Collaborator: University of Pisa. ClinicalTrials.gov Identifier: NCT01223248.
[7]	Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer. Verified October 2014 by Grupo de Investigación Clínica en Oncología Radioterapia. Sponsor: Grupo de Investigación Clínica en Oncología Radioterapia ClinicalTrials.gov Identifier: NCT02192788.
[8]	Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re‑Irradiation. Verified June 2014 by University of Texas Southwestern Medical Center Sponsor: University of Texas Southwestern Medical Center.
[9]	Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re‑Irradiation. Verified March 2015 by University of Texas Southwestern Medical Center ClinicalTrials.gov Identifier: NCT02170181.
[10]	Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate cancer (OLIGOPELVIS) Verified October 2014 by Institut Cancerologie de l'Ouest. Sponsor: Institut Cancerologie de l'Ouest. ClinicalTrials.gov Identifier: NCT02274779.
[11]	Percutaneous High‑dose Radiotherapy in Patients With oligometastases of prostate carcinoma (Oli‑P). Verified November 2014 by Technische Universität Dresden. Sponsor: Technische Universität Dresden. ClinicalTrials.gov Identifier: NCT02264379.
[12]	Tree AC, Khoo VS, Eeles RA (2013): Stereotactic body radiotherapy for oligometastases. Lancet Oncol; 14: e28–37.
[13]	Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, Guminski A, Eade T (2018) Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. Dec; 1(6): 531-537. doi: 10.1016/j.euo.2018.04.017.
[14]	Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C (2019) Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. Int J Cancer. Jun 14. doi: 10.1002/ijc.32509
[15]	Rectal Cancer. NCCN Guidelines. Version 4.13. NCCN.org.
[16]	Non Small Cell Lung Cancer. NCCN Guidelines. Version 2.13. NCCN.org.
[17]	Paget S (1889): The distribution of secondary growths in cancer of the breast. Lancet 1: 571‑573.
[18]	Hellman S, Weichselbaum RR (1995): Oligometastases: J Clin Oncol 13, 1: 8‑10.
[19]	Nguyen DX, Massague´ J (2007): Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341‑35220.
[20]	Gangaraju VK, Lin H, (2009) MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol; 10: 116–25.
[21]	Leong SM, Tan KM, Chua HW, Huang MC, Cheong WC, Li MH, Tucker S, Koay ES 2017 Paper-Based MicroRNA Expression Profiling from Plasma and Circulating Tumor Cells. Clin Chem. Mar; 63(3):731-741. doi: 10.1373/ clinchem.2016.264432.
[22]	Baranwal S, Alahari S (2010): miRNA control of tumor cell invasion and metástasis. Int J Cancer. March 15; 126(6): 1283–1290.
[23]	Li S, Zhang J, Zhao Y, Wang F, Chen Y, Fei X ( 2018) miR-224 enhances invasion and metastasisby targeting HOXD10 in non-small cell lung cancer cells. Oncol Lett. May; 15(5):7069-7075. doi: 10.3892/ol.2018.8245.
[24]	Liu B, Shyr Y, Cai J, Liu Q (2018) Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics. Jul 22; 18(4): 255-266. doi: 10.1093/bfgp/elz002.
[25]	Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126(5): 1166–1176.
[26]	Xu A, Sun S (2015). Genomic profiling screens small molecules of metastatic prostate carcinoma. Oncol Lett. Sep; 10(3): 1402-1408. Epub 2015 Jul 8.
[27]	Nabavi N, Saidy NRN, Venalainen E, Haegert A, Parolia A, Xue H, Wang Y, Wu R, Dong X, Collins C, Crea F, Wang Y (2017) miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Sci Rep. 2017 Jun 22; 7(1): 4079. doi: 10.1038/s41598-017-03731-8.
[28]	McDonald AC, Vira M, Walter V, Shen J, Raman JD, Sanda MG, Patil D, Taioli E.(2019) –Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. Prostate. Jun; 79(9): 961-968. doi: 10.1002/pros.23803.
[29]	Sita‑Lumsden A, Dart DA, Waxman J, Bevan CL. (2013) Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer. May 28; 108(10): 1925‑30.
[30]	Walter BA, Valera VA, Pinto PA, Merino MJ (2013).: Comprehensive microRNA Profiling of prostate Cancer. J Cancer. May 9; 4(5): 350‑7.
[31]	Nam RK, Wallis CJD, Amemiya Y, Benatar T, Seth A (2018) Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer Anticancer Res. Sep; 38(9): 5027-5034. doi: 10.21873/anticanres.12821.
[32]	Li D, Hao X, Song Y.(2018) Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods. Biomed Res Int. Jun 20: 6204128. doi: 10.1155/2018/6204128.
[33]	Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S (2016): Detection of miRNAs in urine of prostate cancer patients Medicina (Kaunas) 5 2 (1 1 6 – 1 2 4).
[34]	Ma W, Ma CN, Li X, Zhang (2016): J Examining the effect of gene reduction in miR‑95 and enhanced radiosensitivity in non‑small cell lung cancer. Cancer Gene Therapy 1–6.
[35]	Fan B, Jiao BH, Fan FS, Lu SK, Song J, Guo CY, Yang JK y Ya L (2015). Downregulation of miR‑95‑3p inhibits proliferation, and invasion promoting apoptosis of glioma cells by targeting CELF2. Int. J of Oncology 47: 1025‑1033.
[36]	Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM (2009) Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23: 2140 – 2151.
[37]	Lussier Y, Xing HR, Salama J, Khodarev NN, Huang Y, et al (2011): Micro RNA expression characterizes oligometastasis. PlosOne 6 (12) 1‑10.
[38]	Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Carsten S, et al (2010). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010 Mar 1; 126(5): 1166‑76.
[39]	Chunfeng He, Qingchuan Zhan, Renze Gu, Yujiao Lou, Wei Liu (2018): miR‐96 regulates migration and invasion of bladder cancer through epithelial‐mesenchymal transition in response to transforming growth factor‐β1. J Cell Biochem.; 1–11.
[40]	Formosa A, Markert EK, Lena AM, Italiano D, Finazzi‑Agro E, vet al (2014): MicroRNAs, miR‑154, miR‑299‑5p, miR‑376a, miR‑376c, miR‑377, miR‑381, miR‑487b, miR‑485‑3p, miR‑495 and miR‑654‑3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 33, 5173–5182
[41]	Lu M, Wang C, Chen W, Mao C, Wang J (2018). miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling. DNA Cell Biol. Apr; 37(4): 381-388. doi: 10.1089/dna.2017.4095. Epub 2018 Jan 24.
[42]	Geraldo MV, et al. (2017) Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Oncotarget, Feb 7. PMID 28030816,
[43]	Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R et al (2011):. Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells. Cancer Res 71: 1956‑1967.
[44]	Lekchnov EA, Amelina EV, Bryzgunova OE, Zaporozhchenko IA, Konoshenko MY, Yarmoschuk SV, Murashov IS, Pashkovskaya OA, Gorizkii AM, Zheravin AA, Laktionov PP. (2018) Searching for the Novel Specific Predictors of Prostate Cancer in Urine: Analysis of 84 miRNA Expression. Int J Mol Sci. Dec 17; 19(12). pii: E4088. doi: 10.3390/ijms19124088.
[45]	Zedan AH, Hansen TF, Assenholt J, Pleckaitis M, Madsen JS, Osther PS (2018): microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer. Tumour Biol. 40(5): 1010428318775864.

Cite This Article

Plain Text BibTeX RIS

APA Style

Carlos Ferrer Albiach, Enrique Ochoa Aranda, Alfonso Gomez Iturriaga-Piña, Amalia Sotoca Ruiz, Fernando López Campos, et al. (2019). MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. Journal of Cancer Treatment and Research, 7(2), 33-40. https://doi.org/10.11648/j.jctr.20190702.12

Copy | Download

ACS Style

Carlos Ferrer Albiach; Enrique Ochoa Aranda; Alfonso Gomez Iturriaga-Piña; Amalia Sotoca Ruiz; Fernando López Campos, et al. MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. J. Cancer Treat. Res. 2019, 7(2), 33-40. doi: 10.11648/j.jctr.20190702.12

Copy | Download

AMA Style

Carlos Ferrer Albiach, Enrique Ochoa Aranda, Alfonso Gomez Iturriaga-Piña, Amalia Sotoca Ruiz, Fernando López Campos, et al. MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. J Cancer Treat Res. 2019;7(2):33-40. doi: 10.11648/j.jctr.20190702.12

Copy | Download

@article{10.11648/j.jctr.20190702.12,
  author = {Carlos Ferrer Albiach and Enrique Ochoa Aranda and Alfonso Gomez Iturriaga-Piña and Amalia Sotoca Ruiz and Fernando López Campos and Mariano Porras Martinez and Raquel García Gómez and Manel Algara Lopez and Virginia Ramos Fernandez and Antonio Conde Moreno and Susana Ors and Esther Flores and Francisco Garcia Piñón},
  title = {MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {7},
  number = {2},
  pages = {33-40},
  doi = {10.11648/j.jctr.20190702.12},
  url = {https://doi.org/10.11648/j.jctr.20190702.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20190702.12},
  abstract = {The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer
AU  - Carlos Ferrer Albiach
AU  - Enrique Ochoa Aranda
AU  - Alfonso Gomez Iturriaga-Piña
AU  - Amalia Sotoca Ruiz
AU  - Fernando López Campos
AU  - Mariano Porras Martinez
AU  - Raquel García Gómez
AU  - Manel Algara Lopez
AU  - Virginia Ramos Fernandez
AU  - Antonio Conde Moreno
AU  - Susana Ors
AU  - Esther Flores
AU  - Francisco Garcia Piñón
Y1  - 2019/08/06
PY  - 2019
N1  - https://doi.org/10.11648/j.jctr.20190702.12
DO  - 10.11648/j.jctr.20190702.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 33
EP  - 40
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20190702.12
AB  - The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.
VL  - 7
IS  - 2
ER  -

Copy | Download

Author Information

Carlos Ferrer Albiach

Radiation Oncology Department, Provincial Hospital Consortium of Castellón, Castellón, Spain
Enrique Ochoa Aranda

Molecular Biology Department, Provincial Hospital Consortium of Castellón, Castellón, Spain
Alfonso Gomez Iturriaga-Piña
Amalia Sotoca Ruiz

Radiation Oncology, International Hospital Ruber, Madrid, Spain
Fernando López Campos

Radiation Oncology, Hospital Ramony Cajal, Madrid, Spain
Mariano Porras Martinez

Radiation Oncology, Hospital Virgen de la Arrixaca, Murcia, Spain
Raquel García Gómez

Radiation Oncology, Hospital Virgen de la Arrixaca, Murcia, Spain
Manel Algara Lopez

Radiation Oncology, lmar Hospital, Barcelona, Spain
Virginia Ramos Fernandez

Pathology Department, Private Laboratory Dra Ramos, Valencia, Spain
Antonio Conde Moreno

Radiation Oncology Department, University Hospital la Fe, Valencia, Spain
Susana Ors

Molecular Biology Department, Provincial Hospital Consortium of Castellón, Castellón, Spain
Esther Flores

Molecular Biology Department, Provincial Hospital Consortium of Castellón, Castellón, Spain
Francisco Garcia Piñón

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Carlos Ferrer Albiach, Enrique Ochoa Aranda, Alfonso Gomez Iturriaga-Piña, Amalia Sotoca Ruiz, Fernando López Campos, et al. (2019). MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. Journal of Cancer Treatment and Research, 7(2), 33-40. https://doi.org/10.11648/j.jctr.20190702.12

Copy | Download

ACS Style

Carlos Ferrer Albiach; Enrique Ochoa Aranda; Alfonso Gomez Iturriaga-Piña; Amalia Sotoca Ruiz; Fernando López Campos, et al. MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. J. Cancer Treat. Res. 2019, 7(2), 33-40. doi: 10.11648/j.jctr.20190702.12

Copy | Download

AMA Style

Carlos Ferrer Albiach, Enrique Ochoa Aranda, Alfonso Gomez Iturriaga-Piña, Amalia Sotoca Ruiz, Fernando López Campos, et al. MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer. J Cancer Treat Res. 2019;7(2):33-40. doi: 10.11648/j.jctr.20190702.12

Copy | Download

@article{10.11648/j.jctr.20190702.12,
  author = {Carlos Ferrer Albiach and Enrique Ochoa Aranda and Alfonso Gomez Iturriaga-Piña and Amalia Sotoca Ruiz and Fernando López Campos and Mariano Porras Martinez and Raquel García Gómez and Manel Algara Lopez and Virginia Ramos Fernandez and Antonio Conde Moreno and Susana Ors and Esther Flores and Francisco Garcia Piñón},
  title = {MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {7},
  number = {2},
  pages = {33-40},
  doi = {10.11648/j.jctr.20190702.12},
  url = {https://doi.org/10.11648/j.jctr.20190702.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20190702.12},
  abstract = {The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer
AU  - Carlos Ferrer Albiach
AU  - Enrique Ochoa Aranda
AU  - Alfonso Gomez Iturriaga-Piña
AU  - Amalia Sotoca Ruiz
AU  - Fernando López Campos
AU  - Mariano Porras Martinez
AU  - Raquel García Gómez
AU  - Manel Algara Lopez
AU  - Virginia Ramos Fernandez
AU  - Antonio Conde Moreno
AU  - Susana Ors
AU  - Esther Flores
AU  - Francisco Garcia Piñón
Y1  - 2019/08/06
PY  - 2019
N1  - https://doi.org/10.11648/j.jctr.20190702.12
DO  - 10.11648/j.jctr.20190702.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 33
EP  - 40
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20190702.12
AB  - The oligometastatic status in the prostate is a new entity of metastatic patients in which their treatment allows to improve survival over standard treatments. There are several theories about their biological origin, one of them being alterations in the expression of miRNas This. was a retrospective multicentre study undertaken in patients with oligometastatic prostate cancer who were diagnosed and treated at one of 7 different Spanish healthcare centres. METHODS: The study included 22 patients; healthy and primary tumour biopsy tissue was analysed in 7+2 of them in order to determine if they had a characteristic microRNA expression profile. We quantified the expression of the following miRNAs: mir‑200a, mir‑200b, mir‑200c, mir‑210, mir‑95, mir‑96, mir‑654‑3p, mir‑543‑3p, mir‑21, mir‑16‑5p, mir‑191‑5p, and mir‑93‑5p, with the latter three being endogenous‑expression controls. RESULTS: Our results show that miRNA95, and to a lesser extent, miRNA654‑3p, were significantly underexpressed (or their expression was suppressed) in tumour tissue samples compared to normal perilesional tissue in all our patients; miRNA95 was underexpressed in 67% of the patients in our sample However, we detected no relationship between miRNA95 expression and the Gleason scores obtained for our patients. CONCLUSIONS: The simple size in our series are limited, but they do allow us to infer that there could be a specific miRNA expression signature in oligometastatic patients with prostate cancer, which may be of great interest in the development of future clinical trials and subsequent studies.
VL  - 7
IS  - 2
ER  -

Copy | Download